HoYoverse has officially shed light on the details of the upcoming character and weapon banners that the Phase 2 update will bring to the game. If you’re a fan of Genshin Impact, there’s plenty of new ...
OS Ther­a­pies is mov­ing ahead with plans for an ac­cel­er­at­ed ap­proval path­way af­ter its off-the-shelf can­di­date for peo­ple who have had surgery to treat os­teosar­co­ma … ...
1 Lagmay JP, Krailo MD, Dang H, et al: Outcome of patients with recurrent osteosarcoma enrolled in seven Phase II trials through Children's Cancer Group, Pediatric Oncology Group, and Children's ...
About TROPOS (NCT05975905) TROPOS is a randomized, double-blind, placebo-controlled, global Phase 2 clinical trial to evaluate cibotercept in combination with background therapy in patients with PAH.
Get Instant Summarized Text (Gist) Trastuzumab emtansine (T-DM1) significantly improves long-term survival in high-risk HER2-positive breast cancer patients post-surgery, reducing the risk of ...
Read on to learn more about the project + what’s next. Broad Metro acquires 121.3 acres for Stadium Trace Village Phase II Broad Metro is kicking off the New Year with a key acquisition for the next ...
If you have already registered (you already have a username and password), please click on the Get Started below. Your account number is located in the upper left hand corner on your address label ...
Credit: MillaF / Shutterstock. Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics have reported positive topline data from Hengrui’s Phase II obesity trial, considering an 8mg dose of the ...
Also on Monday, the company unveiled topline Phase II data for HRS9531, a subcutaneous dual agonist of the GLP-1 and GIP receptors—a mechanism of action that it shares with Eli Lilly’s tirzepatide. At ...
Hot on the heels of its C5 Carbon helmet, Schuberth has released a carbon fiber version of the popular E2 adventure-style helmet—the Schubert E2 Carbon. Unlike Schuberth’s regular lineup of ...
What about Sunday's action? Here are some key takeaways from Day 2 of this year's wild-card action: We already knew this to some extent, just as we did with C.J. Stroud at the close of the 2023 ...